Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Girindus Taps Marina For Oligo Technology

by Rick Mullin
May 28, 2012 | A version of this story appeared in Volume 90, Issue 22

Marina Biotech and Girindus have formed an alliance in which Girindus, a German firm with U.S. operations in Cincinnati, will have exclusive rights to develop, supply, and commercialize oligonucleotide constructs using Marina’s conformationally restricted nucleotide (CRN) technology. Marina, based in Bothell, Wash., will receive royalties from the sale of CRN-based oligo­nucleotide reagents as well as a supply of current Good Manufacturing Practices-certified material for its clinical trials and those run by its partners.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.